Sleep-disordered breathing and positive airway pressure
Untreated OSA has been linked with a number of cardiovascular complications, including hypertension, coronary artery disease, congestive heart failure, cardiac arrhythmias, stroke, and even death.1 In addition to cardiovascular morbidity and mortality, untreated OSA can be associated with multiple other negative effects, including excessive daytime sleepiness, reduced cognitive function (e.g. alertness, motor function, recall ability) and poor quality of life.2 Explore more areas where sleep apnoea has been shown to impact on health related outcomes and everyday life.
CPAP was first described by Professor Colin Sullivan in 1981. Professor Sullivan treated five severe OSA patients with CPAP applied to the nares via tubing and a mask. The CPAP acts as a pneumatic splint which prevents the airway collapsing during sleep. It is considered a safe, non-invasive, highly effective treatment for OSA.3
Continuous positive airway pressure (CPAP) is now widely used and known as the gold standard treatment for OSA. It has been shown to reduce the risk of cardiovascular fatal and non-fatal events and decrease mortality rates compared with untreated OSA4-6. In adherent patients, CPAP therapy has also been shown to significantly improve the symptoms associated with OSA, such as excessive daytime sleepiness, cognitive function and reduced quality of life. 7,8